NCT00805376View on ClinicalTrials.gov

DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Brain CancerCentral Nervous System Diseases
Interventions
DRUG

DNX-2401

Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.

PROCEDURE

Tumor Removal

Surgical Tumor Resection

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

DNAtrix, Inc.
All Listed Sponsors
lead

DNAtrix, Inc.

INDUSTRY

NCT00805376 - DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas | Biotech Hunter | Biotech Hunter